Genomics in multiple myeloma: Biology and clinical implications

Pharmacogenomics

Volumn 6, Issue 6, 2005, Pages 563-573

  Chng, Wee J ^a   Fonseca, Rafael ^a  

^a MAYO CLINIC   (United States)

Author keywords

Fluorescent in situ hybridization; Gene expression; Genetics; Multiple myeloma; Profiling; Prognosis; Targeted therapy

Indexed keywords

BCR ABL PROTEIN; CYCLIN D1; DNA; FIBROBLAST GROWTH FACTOR 3; IMATINIB; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN;

ACCURACY; ANEUPLOIDY; B LYMPHOCYTE; CHROMOSOME 11Q; CHROMOSOME 13; CHROMOSOME 14Q; CHROMOSOME 16Q; CHROMOSOME 4P; CHROMOSOME 6P; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 4; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG RESPONSE; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC STABILITY; GENOMICS; HUMAN; MEDICAL RESEARCH; MOLECULAR EVOLUTION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; ONCOGENE; PATHOGENESIS; PATIENT SELECTION; PHARMACOGENOMICS; PLASMACYTOMA; PROGNOSIS; REVIEW; RISK ASSESSMENT; SOMATIC MUTATION; UPREGULATION;

DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FORECASTING; GENETIC HETEROGENEITY; GENOMICS; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PATIENT SELECTION; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 25144454122     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.6.563     Document Type: Review

References (92)

1. Kyle RA, Rajkumar SV: Multiple myeloma. N. Engl. J. Med. 351, 1860-1873 (2004).
2. Hann I, Vora A, Harrison G et al.: Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 113, 103-114 (2001).
3. Harrison CJ, Foroni L: Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev. Clin. Exp. Hematol. 6, 91-113; discussion 200-212 (2002).
4. Byrd JC, Mrozek K, Dodge RK et al.: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325-4336 (2002).
5. Grimwade D: The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract. Res. Clin. Haematol. 14, 497-529 (2001).
6. Grimwade D, Walker H, Harrison G et al.: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312-1320 (2001).
7. Bullinger L, Dohner K, Bair E et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605-1616 (2004).
8. Ross ME, Zhou X, Song G et al.: Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102, 2951-2959 (2003).
9. Valk PJ, Verhaak RG, Beijen MA et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 350, 1617-1628 (2004).
10. Yeoh EJ, Ross ME, Shurtleff SA et al.: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143 (2002).
11. Capdeville R, Silberman S: Imatinib: a targeted clinical drug development. Semin. Hematol. 40, 15-20 (2003).
12. Fonseca R, Barlogie B, Bataille R et al.: Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 64, 1546-1558 (2004).
13. Ahmann GJ, Jalal SM, Juneau AL et al.: A novel three-color. clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet. Cytogenet. 101, 7-11 (1998).
14. Avet-Loiseau H, Li JY, Morineau N et al.: Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 94, 2583-2589 (1999).
15. Kyle RA, Therneau TM, Rajkumar SV et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564-569 (2002).
16. Salmon SE: Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin. Hematol. 10, 135-144 (1973).
17. Kyle RA, Greipp PR: Smoldering multiple myeloma. N. Engl. J. Med. 302, 1347-1349 (1980).
18. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC: Advances in biology of multiple myeloma: clinical applications. Blood 104, 607-618 (2004).
19. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121, 749-757 (2003).
20. Kuehl WM, Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. Nature Rev. Cancer 2, 175-187 (2002).
21. Futreal PA, Coin L, Marshall M et al.: A census of human cancer genes. Nature Rev. Cancer 4, 177-183 (2004).
22. Kuppers R: Mechanisms of B-cell lymphoma pathogenesis. Nature Rev. Cancer 5, 251-262 (2005).
23. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM: Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl Acad. Sci. USA 93, 13931-13936 (1996).
24. Bergsagel PL, Kuehl WM: Chromosome translocations in multiple myeloma. Oncogene 20, 5611-5622 (2001).
25. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM: Dysregulation of cyclin D1 by translocation into an IgH γ switch region in two multiple myeloma cell lines. Blood 88, 674-681 (1996).
26. Ronchetti D, Finelli P, Richelda R et al.: Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 93, 1330-1337 (1999).
27. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr: Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1), 296-303 (2005).
28. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ: The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am. J. Clin. Pathol. 113, 831-837 (2000).
29. Fonseca R, Blood EA, Oken MM et al.: Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99, 3735-3741 (2002).
30. Moreau P, Facon T, Leleu X et al.: Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100, 1579-1583 (2002).
31. Mateo G, Castellanos M, Rasillo A et al.: Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin. Cancer Res. 11, 3661-3667 (2005).
32. Robbiani DF, Chesi M, Bergsagel PL: Bone lesions in molecular subtypes of multiple myeloma. N. Engl. J. Med. 351, 197-198 (2004).
33. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R: t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 17, 2032-2035 (2003).
34. Chesi M, Nardini E, Brents LA et al.: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet. 16, 260-264 (1997).
35. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL: The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92, 3025-3034 (1998).
36. Keats JJ, Reiman T, Maxwell CA et al.: In multiple myeloma, t(4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101, 1520-1529 (2003).
37. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr: A subset of multiple myeloma harboring the t(4;14) (p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101, 2374-2376 (2003).
38. Chesi M, Brents LA, Ely SA et al.: Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97, 729-736 (2001).
39. Intini D, Baldini L, Fabris S et al.: Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br. J. Haematol. 114, 362-364 (2001).
40. Onwuazor ON, Wen XY, Wang DY et al.: Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 102, 772-773 (2003).
41. Keats JJ, Maxwell CA, Taylor BJ et al.: Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32) positive multiple myeloma patients. Blood 105, 4060-4069 (2005).
42. Fonseca R, Blood E, Rue M et al.: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101, 4569-4575 (2003).
43. Chesi M, Bergsagel PL, Shonukan OO et al.: Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91, 4457-4463 (1998).
44. Hurt EM, Wiestner A, Rosenwald A et al.: Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5, 191-199 (2004).
45. Podar K, Anderson KC: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105, 1383-1395 (2005).
46. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C: Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98, 2229-2238 (2001).
47. Smadja NV, Fruchart C, Isnard F et al.: Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12, 960-969 (1998).
48. Debes-Marun CS, Dewald GW, Bryant S et al.: Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17, 427-436 (2003).
49. Greipp PR, Trendle MC, Leong T et al.: Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk. Lymphoma 35, 83-89 (1999).
50. Orfao A, Garcia-Sanz R, Lopez-Berges MC et al.: A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 17, 332-339 (1994).
51. Chng WJ, Van Wier SA, Ahmann GJ et al.: A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood (Epub ahead of print) (2005).
52. Wuilleme S, Robillard N, Lode L et al.: Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19(2), 275-278 (2004).
53. Facon T, Avet-Loiseau H, Guillerm G et al.: Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97, 1566-1571 (2001).
54. Fonseca R, Harrington D, Oken MM et al.: Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res. 62, 715-720 (2002).
55. Zojer N, Konigsberg R, Ackermann J. et al.: Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95, 1925-1930 (2000).
56. Avet-Louseau H, Daviet A, Sauner S, Bataille R: Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br. J. Haematol. 111, 1116-1117 (2000).
57. Fonseca R, Oken MM, Harrington D et al.: Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15, 981-986 (2001).
58. Bezieau S, Devilder MC, Avet-Loiseau H et al.: High incidence of N- and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat. 18, 212-224 (2001).
59. Liu P, Leong T, Quam L et al.: Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88, 2699-2706 (1996).
60. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM: Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 105, 317-323 (2005).
61. Avet-Loiseau H, Daviet A, Brigaudeau C et al.: Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 97, 822-825 (2001).
62. Drach J, Ackermann J, Fritz E et al.: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92, 802-809 (1998).
63. Chang H, Sloan S, Li D, Keith Stewart A: Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br. J. Haematol. 127, 280-284 (2004).
64. Ackermann J, Meidlinger P, Zojer N et al.: Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br. J. Haematol. 103, 1161-1163 (1998).
65. Fonseca R, Debes-Marun CS, Picken EB et al.: The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102, 2562-2567 (2003).
66. Smadja NV, Leroux D, Soulier J et al.: Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 38, 234-239 (2003).
67. Fonseca R, Bailey RJ, Ahmann GJ et al.: Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100, 1417-1424 (2002).
68. Avet-Loiseau H, Facon T, Daviet A et al.: 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 59, 4546-4550 (1999).
69. Avet-Loiseau H, Facon T, Grosbois B et al.: Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99, 2185-2191 (2002).
70. Kaufmann H, Ackermann J, Baldia C et al.: Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 18, 1879-1882 (2004).
71. Seidl S, Ackermann J, Kaufmann H et al.: DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 100, 2598-2606 (2004).
72. Davies FE, Dring AM, Li C et al.: Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102, 4504-4511 (2003).
73. Zhan F, Hardin J, Kordsmeier B et al.: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99, 1745-1757 (2002).
74. Mattioli M, Agnelli L, Fabris S et al.: Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24, 2461-2473 (2005).
75. Ashcroft AJ, Davies FE, Morgan GJ: Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol. 4, 284-292 (2003).
76. Glass DA 2nd, Bialek P, Ahn JD et al.: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8, 751-764 (2005).
77. Tian E, Zhan F, Walker R et al.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483-2494 (2003).
78. Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T: Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res. 65, 850-860 (2005).
79. Nigg EA: Centrosome aberrations: cause or consequence of cancer progression? Nature Rev. Cancer 2, 815-825 (2002).
80. Wu K-D, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, Moore MAS: Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 101, 4982-4989 (2003).
81. Nelsen CJ, Kuriyama R, Hirsch B et al.: Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J. Biol. Chem. 280, 768-776 (2005).
82. Fonseca R, Oken MM, Greipp PR: The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 98, 1271-1272 (2001).
83. Trudel S, Ely S, Farooqi Y et al.: Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103, 3521-3528 (2004).
84. Paterson JL, Li Z, Wen XY et al.: Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br. J. Haematol. 124, 595-603 (2004).
85. Trudel S, Li ZH, Wei E et al.: CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105, 2941-2948 (2005).
86. Zhu L, Somlo G, Zhou B et al.: Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol. Cancer Ther. 4, 787-798 (2005).
87. Chauhan D, Auclair D, Robinson EK et al.: Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 21, 1346-1358 (2002).
88. Chauhan D, Li G, Auclair D et al.: Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 101, 3606-3614 (2003).
89. Mitsiades CS, Mitsiades NS, McMullan CJ et al.: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA 101, 540-545 (2004).
90. Mitsiades N, Mitsiades CS, Poulaki V et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99, 14374-14379 (2002).
91. Hazlehurst LA, Enkemann SA, Beam CA et al.: Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 63, 7900-7906 (2003).
92. Zhou P, Kalakonda N, Comenzo RL: Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br. J. Haematol. 128, 636-644 (2005).